John A. Blake-Haskins

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Se Hoon Park, Éric Voog et al. · New England Journal of Medicine · 2020 · 1.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 845 citations · Full text

Medicine, Oncology, Urology +17

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Marlon C. Rebelatto, Anita Midha, Amita Mistry et al. · Diagnostic Pathology · 2016 · 179 citations · Full text

Medicine, Oncology, Cancer Immunology +16

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Naiyer A. Rizvi, Julie R. Brahmer, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2015 · 164 citations

Pharmacy, Oncology, Pharmacology +17

Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.

Antoni Ribas, Marcus O. Butler, Jose Lutzky et al. · Journal of Clinical Oncology · 2015 · 152 citations

Pharmacy, Pharmacology, Pharmacotherapy +17